drugset / Trial / NCT05116891
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase 1/2, open-label, multicentric, non-randomised, parallel-arm study that aims to establish the safety, tolerability, and initial efficacy of CAN04 in combination with 3 SoC chemotherapies (mFOLFOX, DTX, and G/C).
Timeline
- Start
- 2021-09-22
- Primary completion
- 2023-06-23
- Completion
- 2023-06-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NIDANILIMAB | Monoclonal antibody | — | — |
| Background | Cisplatin | Other / unclassified | — | — |
| Background | DTX | Unknown | — | — |
| Background | Gemcitabine | Small molecule | — | — |
| Background | Leucovorin | Small molecule | — | — |
| Background | Oxaliplatin | Small molecule | — | — |
| Background | fluorouracil | Small molecule | — | — |